dgn-np:NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_provenance {
  dgn-np:NP294219.RA_Gg-gbtNlsZr-fBCXmhl3V7efJG2hjvQkBOMmNtxDgs130_assertion dcterms:description "[Although the first Moss study reported a significant improvement in respiratory function (FEV(1)) 30 days after participants had received their first dose of gene therapy agent, this finding was not confirmed in their larger second study or in our meta-analysis.In participants who received the CFTR gene transfer agents in the Alton study, `influenza-like` symptoms were found (relative risk 7.00 (95% confidence interval (CI) 1.10 to 44.61)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ;
    wi:evidence dgn-void:source_evidence_literature ;
    sio:SIO_000772 miriam-pubmed:17443603 ;
    prov:wasDerivedFrom dgn-void:befree-20140225 ;
    prov:wasGeneratedBy eco:ECO_0000203 .
  dgn-void:befree-20140225 pav:importedOn "2014-02-25"^^xsd:date .
  dgn-void:source_evidence_literature a eco:ECO_0000212 ;
    rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en ;
    rdfs:label "DisGeNET evidence - LITERATURE"@en .
}